50. When researchers are studying the effect of new drug treatments on patients, bias can be introduced by patients if they are aware of who receives the placebo. Which type of research design eliminates this type of bias?
Answer: B
Blind study eliminates bias related to patient awareness of treatment allocation.
A blind study ensures that participants do not know whether they are receiving the treatment or a placebo, which effectively minimizes any bias that could arise from their awareness of the treatment they are assigned.
A) Prospective cohort study
A prospective cohort study involves observing a group of individuals over time to assess outcomes based on exposure to certain factors. However, this design does not control for bias related to participants knowing their treatment allocation, as they may still be aware of whether they are receiving the drug or placebo.
B) Blind study
A blind study is specifically designed to prevent participants from knowing whether they are receiving the experimental treatment or a placebo. This lack of awareness helps to eliminate bias that could affect the study outcomes, making it the most effective design in this context.
C) Observational study
An observational study involves watching subjects without intervening or assigning treatments. This design does not eliminate bias, as participants might know their treatment status, which can influence their responses or behaviors and ultimately skew the results.
D) Time series study
A time series study examines data points collected at multiple time intervals to observe trends. Similar to observational studies, this design does not address bias from participants being aware of whether they are in a treatment or placebo group, thus it does not effectively eliminate treatment allocation bias.
Conclusion
The blind study is uniquely effective in eliminating bias related to patient awareness of treatment allocation, which can significantly impact study results. Other designs, such as prospective cohort, observational, and time series studies, do not adequately control for this bias, making them less suitable for research focused on assessing drug treatment effects.